X

Trial Profile

A Phase II Trial of CD24Fc for Prevention of Acute Graft-versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplant

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 13 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Efprezimod alfa (Primary) ; Methotrexate; Tacrolimus; Tacrolimus
Indications Graft-versus-host disease
Focus Adverse reactions; Proof of concept; Therapeutic Use
Sponsors OncoImmune

Most Recent Events

30 Aug 2023 Primary endpoint has been met, (Open Label Expansion Arm Only: Grade III-IV Acute Graft-Versus-Host Disease (GVHD) Free Survival (AGFS), as per Results published in the Blood
30 Aug 2023 Results published in the Blood
23 Apr 2021 Planned End Date changed from 30 Apr 2021 to 5 May 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com